Bayer’s Parkinson Gene Therapy Breaks New Ground as Investors Push for a Breakup

Bayer shares fall 7% as gene therapy milestone contrasts with shareholder demands for restructuring, glyphosate litigation, and weak 2026 outlook.

The German life sciences group finds itself caught between two very different narratives: a promising clinical milestone in gene therapy and mounting pressure from shareholders who want the conglomerate dismantled. The tension between scientific progress and corporate restructuring has rarely been so stark.

Shares in Bayer have slipped to around €37, after shedding roughly 7 percent over the past week. The stock now trades about a quarter below the February peak of nearly €49.50, with the latest leg lower reflecting a combination of the ex-dividend adjustment and lingering disappointment over the 2026 profit outlook that first hit the shares in March.

A Rare Pipeline Bright Spot

Bayer’s gene therapy subsidiary AskBio has quietly achieved something that has eluded many in the field. The company completed an IND amendment with the FDA for its Parkinson’s candidate Ametefgene Parvec (AB-1005), clearing the way for the Phase II REGENERATE-PD study to be supplied with material from Viralgen’s commercial-scale manufacturing facility. For gene therapies, the leap from clinical-grade to commercial-scale production is a notorious bottleneck — AskBio’s ability to clear that hurdle bolsters the credibility of the entire pipeline.

The progress comes at a time when Bayer’s pharmaceutical division is navigating what Barclays expects to be a trough year in 2026, with a return to mid-single-digit growth not anticipated until 2027. Two key drugs, Nubeqa and Kerendia, grew a combined 68 percent last year and are central to offsetting the decline of older products.

The Roundup Shadow Lengthens

None of this changes the fact that the glyphosate litigation remains the single biggest overhang on the stock. Monsanto has filed its opening brief with the U.S. Supreme Court in the Durnell case, which challenges whether federal labeling requirements preempt state-level claims. A favorable ruling could materially narrow the scope of future lawsuits, but concrete signals from the court are still absent.

The legal uncertainty is one reason institutional investors have sharpened their tone following the annual general meeting on April 24. Ingo Speich of Deka has called 2026 the “year of decision” for Bayer and CEO Bill Anderson, with Union Investment echoing the sentiment. While the operational progress — including the elimination of roughly 14,000 positions — is acknowledged, it is no longer enough. Major shareholders are now demanding an open-ended review of the group’s structure, with a potential breakup squarely on the table.

Cash Preservation and Cost of Confidence

The dividend policy underscores the balancing act. Bayer paid out only the statutory minimum of €0.11 per share for 2025, with the distribution scheduled for April 29. The move conserves liquidity but does little to reassure income-focused investors.

Thirteen analysts still rate the stock a buy, with an average price target of €47.63. But the gap between that target and the current share price reflects a market that is pricing in considerable downside risk from both the litigation and the structural uncertainty.

What Comes Next

Bayer will publish its first-quarter results on May 12, giving investors their first look at profitability trends in the Crop Science division and the trajectory of net debt, which had edged lower in the previous period. That data point will arrive against the backdrop of a Supreme Court decision that could reshape the entire risk profile of the company.

For now, Bayer presents an unusual picture: a conglomerate with a gene therapy platform that is hitting technical milestones, a pharmaceutical pipeline that is rebuilding, and a shareholder base that is running out of patience with the status quo. The next few weeks will test whether the operational story can regain the upper hand over the structural one.